Modern Chinese Medicine Group (SEHK:1643) Half Year Profit Challenges Ongoing Loss Narrative
Simply Wall St·04/01/2026 10:34:09
Listen to the news
Modern Chinese Medicine Group (SEHK:1643) has opened FY 2025 with first half revenue of C¥64.8 million and basic EPS of C¥0.0041, setting a cautious tone against a recent history of mixed earnings. Over the past three reported half year periods, revenue has moved from C¥76.6 million in 1H 2024 to C¥137.4 million in 2H 2024 and C¥64.8 million in 1H 2025. Basic EPS shifted from a loss of C¥0.0114 in 1H 2024 to C¥0.0275 in 2H 2024 and C¥0.0041 in the latest half, leaving investors focused on how sustainably margins can stabilise from here.
With the headline numbers set, the next step is to see how these results line up with the prevailing narratives around growth, profitability and risk, and where the latest figures start to challenge those stories.
SEHK:1643 Earnings & Revenue History as at Apr 2026
Trailing 12‑Month Losses Versus 1H Profit
On a trailing 12‑month basis, the company recorded total revenue of C¥145.2 million and a net loss of C¥13.6 million, even though 1H 2025 on its own shows C¥64.8 million of revenue and C¥2.5 million of net income.
Bears point to the 35.8% annualised worsening of losses over five years, and the latest data leans their way because:
The trailing 12‑month net loss of C¥13.6 million contrasts with positive net income of C¥2.5 million in 1H 2025 and C¥16.5 million in 2H 2024, so the recent profit halves have not yet turned the longer record into a profit.
Basic EPS is C¥0.0041 in 1H 2025, but the trailing 12‑month Basic EPS is a C¥0.0205 loss, which fits the picture of longer term earnings pressure that critics highlight.
High P/S Multiple Against Peers
The current P/S ratio of 8.8x sits well above the peer average of 1.7x and the Hong Kong Pharmaceuticals industry average of 2.9x. The share price of HK$2.01 is also above the C¥0.0205 trailing 12‑month loss per share.
What stands out for a bearish view is how valuation stretches against fundamentals because:
The share price of HK$2.01 is compared with a DCF fair value of HK$0.38, so the stock is trading at more than 5x that modelled level, despite the business being loss making over the trailing 12 months.
With losses having grown at about 35.8% per year over five years and no rewards highlighted in the trailing data, the premium P/S and the gap to DCF fair value focus attention on execution risk rather than upside.
On this kind of risk heavy setup, many investors want to see how cautious and bullish cases are built from the same numbers before making a call. It is therefore worth reading both sides in the full bear case narrative for Modern Chinese Medicine Group 🐻 Modern Chinese Medicine Group Bear Case.
Swings Between Loss and Profit
Net income has moved from a loss of C¥6.9 million in 1H 2024 to a profit of C¥16.5 million in 2H 2024, then C¥2.5 million in 1H 2025, while the trailing 12‑month figures still show a C¥13.6 million loss.
For a more balanced, general market read, the pattern creates tension between recent halves and the longer record because:
Basic EPS moved from a C¥0.0114 loss in 1H 2024 to C¥0.0275 in 2H 2024 and C¥0.0041 in 1H 2025, yet the trailing 12‑month EPS is still a C¥0.0205 loss, so shorter term improvements have not fully offset earlier weakness.
Trailing 12‑month revenue of C¥145.2 million is lower than the C¥202.2 million and C¥214.1 million figures seen in earlier trailing windows, which ties into concerns about earnings durability when combined with five year loss growth of 35.8% a year.
To see how investors with different risk appetites are interpreting these swings, it helps to step back from the raw numbers and read a broader narrative built around them. You can do this through the community focused view on Modern Chinese Medicine Group 📊 Read the what the Community is saying about Modern Chinese Medicine Group..
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Modern Chinese Medicine Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
Given the mixed tone of these results, it makes sense to review the underlying figures yourself and decide how comfortable you are with the risk profile. To round out that view, take a moment to review the 3 important warning signs.
Explore Alternatives
Modern Chinese Medicine Group combines a trailing 12 month loss, volatile earnings and a P/S multiple far above peers, which raises clear valuation and execution concerns.
If you are uneasy about paying a premium for inconsistent results, shift your attention to companies screened as 253 high quality undervalued stocks that could offer a more grounded entry point.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure. Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities. This should not be construed as an investment advice and does not constitute an offer, solicitation, opinion, or any guarantee of any investment product, nor does it constitute any investment recommendation. Investments involve risks, Investment products prices are subject to fluctuation and may rise or fall (including the possibility of loss of the capital invested). Past performance is not indicative of future results. Before making any investment decision, investors should carefully consider your own risk tolerance, financial situation, investment experience, and objectives, or consult professional investment advisors to make a rational decision.